PharmaEngine (4162) — Capital Reinvestment Ratio
PharmaEngine (4162) has a Capital Reinvestment Ratio of 0.00x as of September 2025, meaning it reinvests 0% of its operating cash flow (NT$53.01 Million) in capital expenditures (NT$115.00K). See debt-free asset ratio of PharmaEngine to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
PharmaEngine Capital Reinvestment Ratio (2011–2024)
This chart tracks PharmaEngine's Capital Reinvestment Ratio across 12 annual periods. Check 4162 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for PharmaEngine (2011–2024)
Year-by-year Capital Reinvestment Ratio for PharmaEngine from 2011 to 2024. For live market cap and broader valuation context, see how much is PharmaEngine worth.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.00x | NT$456.73 Million | NT$1.42 Million | ▼ -16.9% |
| 2023 | 0.00x | NT$256.97 Million | NT$958.00K | ▼ -80.9% |
| 2022 | 0.02x | NT$202.01 Million | NT$3.94 Million | ▲ +7825.9% |
| 2021 | 0.00x | NT$929.67 Million | NT$229.00K | ▼ -97.4% |
| 2020 | 0.01x | NT$64.77 Million | NT$608.00K | ▼ -27.4% |
| 2019 | 0.01x | NT$16.08 Million | NT$208.00K | ▲ +1790.4% |
| 2018 | 0.00x | NT$745.23 Million | NT$510.00K | ▼ -48.0% |
| 2016 | 0.00x | NT$870.38 Million | NT$1.15 Million | ▼ -95.0% |
| 2015 | 0.03x | NT$447.99 Million | NT$11.80 Million | ▲ +3535.1% |
| 2014 | 0.00x | NT$131.09 Million | NT$95.00K | ▼ -40.1% |
| 2012 | 0.00x | NT$68.64 Million | NT$83.00K | ▼ -58.7% |
| 2011 | 0.00x | NT$275.49 Million | NT$806.00K | — |